Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Accumulated Depreciation (2016 - 2025)

Amphastar Pharmaceuticals has reported Accumulated Depreciation over the past 13 years, most recently at $306.3 million for Q4 2025.

  • Quarterly results put Accumulated Depreciation at $306.3 million for Q4 2025, up 12.77% from a year ago — trailing twelve months through Dec 2025 was $306.3 million (up 12.77% YoY), and the annual figure for FY2025 was $306.3 million, up 12.77%.
  • Accumulated Depreciation for Q4 2025 was $306.3 million at Amphastar Pharmaceuticals, up from $298.3 million in the prior quarter.
  • Over the last five years, Accumulated Depreciation for AMPH hit a ceiling of $306.3 million in Q4 2025 and a floor of $189.2 million in Q1 2021.
  • Median Accumulated Depreciation over the past 5 years was $235.1 million (2023), compared with a mean of $239.4 million.
  • Biggest five-year swings in Accumulated Depreciation: grew 6.6% in 2022 and later rose 12.77% in 2025.
  • Amphastar Pharmaceuticals' Accumulated Depreciation stood at $199.6 million in 2021, then rose by 10.22% to $220.0 million in 2022, then grew by 11.48% to $245.3 million in 2023, then grew by 10.72% to $271.6 million in 2024, then increased by 12.77% to $306.3 million in 2025.
  • The last three reported values for Accumulated Depreciation were $306.3 million (Q4 2025), $298.3 million (Q3 2025), and $290.5 million (Q2 2025) per Business Quant data.